Serotonin receptor-mediated vasorelaxation occurs primarily through 5-HT4 activation in bovine lateral saphenous vein

被引:0
|
作者
Trotta, Ronald J. [1 ]
Harmon, David L. [1 ]
Klotz, James L. [2 ]
机构
[1] Univ Kentucky, Dept Anim & Food Sci, Lexington, KY USA
[2] USDA ARS, Forage Anim Prod Res Unit, Lexington, KY 40503 USA
来源
PHYSIOLOGICAL REPORTS | 2024年 / 12卷 / 13期
关键词
5-hydroxytryptamine; BIMU; 8; cattle; G protein-coupled receptor; ruminant; HUMAN CORONARY-ARTERIES; TALL FESCUE; ERGOT ALKALOIDS; 5-HYDROXYTRYPTAMINE-INDUCED RELAXATION; ADENYLATE-CYCLASE; PULMONARY VEIN; CAUDAL ARTERY; AGONIST; SHEEP; CONTRACTILITY;
D O I
10.14814/phy2.16128
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
To better understand mechanisms of serotonin- (5-HT) mediated vasorelaxation, isolated lateral saphenous veins from cattle were assessed for vasoactivity using myography in response to increasing concentrations of 5-HT or selective 5-HT receptor agonists. Vessels were pre-contracted with 1 x 10(-4) M phenylephrine and exposed to increasing concentrations of 5-HT or 5-HT receptor agonists that were selective for 5-HT1B, 5-HT2B, 5-HT4, and 5-HT7. Vasoactive response data were normalized as a percentage of the maximum contractile response induced by the phenylephrine pre-contraction. At 1 x 10(-7) M 5-HT, a relaxation was observed with an 88.7% decrease (p < 0.01) from the phenylephrine maximum. At 1 x 10(-4) M 5-HT, a contraction was observed with a 165% increase (p < 0.01) from the phenylephrine maximum. Increasing concentrations of agonists selective for 5-HT2B, 5-HT4, or 5-HT7 resulted in a 27%, 92%, or 44% (p < 0.01) decrease from the phenylephrine maximum, respectively. Of these 5-HT receptor agonists, the selective 5-HT4 receptor agonist resulted in the greatest potency (-log EC50) value (6.30) compared with 5-HT2B and 5-HT7 receptor agonists (4.21 and 4.66, respectively). To confirm the involvement of 5-HT4 in 5-HT-mediated vasorelaxation, blood vessels were exposed to either DMSO (solvent control) or a selective 5-HT4 antagonist (1 x 10(-5) M) for 5-min prior to the phenylephrine pre-contraction and 5-HT additions. Antagonism of the 5-HT4 receptor attenuated the vasorelaxation caused by 5-HT. Approximately 94% of the vasorelaxation occurring in response to 5-HT could be accounted for through 5-HT4, providing strong evidence that 5-HT-mediated vasorelaxation occurs through 5-HT4 activation in bovine peripheral vasculature.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Participation of a cholinergic mechanism in 5-hydroxytryptamine (5-HT)3 and 5-HT4 receptor-mediated stimulation of gastric emptying in rats
    Yamano, M
    Kamato, T
    Miyata, K
    ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH, 1997, 47 (11): : 1242 - 1246
  • [32] Increased defaecation caused by 5-HT4 receptor activation in the mouse
    Banner, SE
    Smith, MI
    Bywater, D
    Gaster, LM
    Sanger, GJ
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1996, 308 (02) : 181 - 186
  • [33] 5-HT4 receptor-mediated anti-inflammatory potency via nAChR in digestive irritation.
    Hori, Masatoshi
    Tsuchida, Yasuaki
    Fujisawa, Masahiko
    Hatao, Fumihiko
    Murata, Takahisa
    Seto, Yasuyuki
    Ozaki, Hiroshi
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2012, 118 : 50P - 50P
  • [34] Simultaneous PET/fMRI imaging of the serotonin receptor system: the 5-HT4 receptor subtype
    Verwer, E.
    Wooten, D. W.
    Mandeville, J.
    Neelamegam, R.
    Yokell, D. L.
    El Fakhri, G.
    Alpert, N. M.
    Normandin, M. D.
    JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2017, 37 : 236 - 237
  • [35] Serotonin4 (5-HT4) receptor agonists:: rapid-onset antidepressants?
    不详
    NEUROSCIENTIST, 2008, 14 (01): : 7 - 7
  • [36] Fading of 5-HT4 receptor-mediated inotropic responses to 5-hydroxytryptamine is caused by phosphodiesterase activity in porcine atrium
    Kaumann, AJ
    Levy, FO
    BRITISH JOURNAL OF PHARMACOLOGY, 2006, 147 (02) : 128 - 130
  • [37] PERISTALSIS EVOKED BY 5-HT AND RENZAPRIDE - EVIDENCE FOR PUTATIVE 5-HT4 RECEPTOR ACTIVATION
    CRAIG, DA
    CLARKE, DE
    BRITISH JOURNAL OF PHARMACOLOGY, 1991, 102 (03) : 563 - 564
  • [38] Role of prucalopride, a serotonin (5-HT4) receptor agonist, for the treatment of chronic constipation
    Wong, Banny S.
    Manabe, Noriaki
    Camilleri, Michael
    CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY, 2010, 3 : 49 - 56
  • [39] Treatment with a 5-HT4 serotonin receptor antagonist improves function of the failing heart
    Birkeland, J. A. K.
    Sjaastad, I.
    Brattelid, T.
    Qvigstad, E.
    Moberg, E. R.
    Krobert, K. A.
    Bjornerheim, R.
    Skomedal, T.
    Sejersted, O. M.
    Osnes, J. -B.
    Levy, F. O.
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2006, 40 (06) : 943 - 944
  • [40] Treatment with a 5-HT4 serotonin receptor antagonist improves function of the failing heart
    Birkeland, J. A. K.
    Sjaastad, I
    Brattelid, T.
    Qvigstad, E.
    Moberg, E. R.
    Krobert, K. A.
    Bjornerheim, R.
    Skomedal, T.
    Sejersted, O. M.
    Osnes, J. -B.
    Levy, F. O.
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2006, 101 : 75 - 75